MX2009006704A - Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa. - Google Patents

Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.

Info

Publication number
MX2009006704A
MX2009006704A MX2009006704A MX2009006704A MX2009006704A MX 2009006704 A MX2009006704 A MX 2009006704A MX 2009006704 A MX2009006704 A MX 2009006704A MX 2009006704 A MX2009006704 A MX 2009006704A MX 2009006704 A MX2009006704 A MX 2009006704A
Authority
MX
Mexico
Prior art keywords
new compounds
compounds
cancer
diseases
treatment
Prior art date
Application number
MX2009006704A
Other languages
English (en)
Spanish (es)
Inventor
Miles Stuart Congreve
Valerio Berdini
Adrian Liam Gill
Gilbert Ebai Bensong
Maria Grazia Carr
Charlote Mary Griffiths-Jones
Andrew Madin
Christopher William Murray
Rajdeep Kaur Nijjar
Michael Alistair O'brien
Andrew Pike
Gordon Saxty
Emma Vickerstaffe
Richard David Taylor
Owen Callaghan
Original Assignee
Astex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0625827A external-priority patent/GB0625827D0/en
Priority claimed from GB0719998A external-priority patent/GB0719998D0/en
Application filed by Astex Therapeutics Ltd filed Critical Astex Therapeutics Ltd
Publication of MX2009006704A publication Critical patent/MX2009006704A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Enzymes And Modification Thereof (AREA)
MX2009006704A 2006-12-22 2007-12-21 Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa. MX2009006704A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US87153806P 2006-12-22 2006-12-22
GB0625827A GB0625827D0 (en) 2006-12-22 2006-12-22 New compounds
US97958207P 2007-10-12 2007-10-12
GB0719998A GB0719998D0 (en) 2007-10-12 2007-10-12 New compounds
PCT/GB2007/004960 WO2008078100A2 (en) 2006-12-22 2007-12-21 Tricyclic amine derivatives as protein tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2009006704A true MX2009006704A (es) 2009-06-30

Family

ID=39322759

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006704A MX2009006704A (es) 2006-12-22 2007-12-21 Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.

Country Status (12)

Country Link
US (1) US8513276B2 (enExample)
EP (1) EP2121687B1 (enExample)
JP (1) JP5442449B2 (enExample)
CN (1) CN101679409B (enExample)
AU (1) AU2007337895C1 (enExample)
CA (1) CA2672213C (enExample)
CY (1) CY1117319T1 (enExample)
HR (1) HRP20151398T1 (enExample)
MX (1) MX2009006704A (enExample)
NO (1) NO342865B1 (enExample)
PL (1) PL2121687T3 (enExample)
WO (1) WO2008078100A2 (enExample)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
WO2008078100A2 (en) 2006-12-22 2008-07-03 Astex Therapeutics Limited Tricyclic amine derivatives as protein tyrosine kinase inhibitors
AR064491A1 (es) * 2006-12-22 2009-04-08 Astex Therapeutics Ltd Derivados de imidazo[1, 2-a]pirimidina, un proceso para su preparacion, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por las quinasas fgfr.
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
MX2010002538A (es) 2007-09-14 2010-08-10 Ortho Mcneil Janssen Pharm 4-(aril-x-fenil)-1h-piridin-2-onas 1,3-disubstituidas.
CA2698929C (en) 2007-09-14 2016-01-19 Addex Pharma S.A. 1,3-disubstituted-4-phenyl-1h-pyridin-2-ones
MY152078A (en) 2007-09-14 2014-08-15 Ortho Mcneil Janssen Pharm 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h,1'h-[1,4']bipyridinyl-2'-ones
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
ES2637794T3 (es) 2007-11-14 2017-10-17 Janssen Pharmaceuticals, Inc. Derivados de imidazo[1,2-A]piridina y su uso como moduladores alostéricos positivos de receptores MGLUR2
KR20100108390A (ko) 2007-12-19 2010-10-06 버텍스 파마슈티칼스 인코포레이티드 ＪＡＫ２ 억제제로서 유용한 피라졸로［１，５－ａ］피리미딘
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
US8518911B2 (en) 2008-08-05 2013-08-27 Merck Sharp & Dohme Corp. Pyrazolo[1,5-a]pyridines as MARK inhibitors
US8455477B2 (en) * 2008-08-05 2013-06-04 Merck Sharp & Dohme Corp. Therapeutic compounds
AU2009289784B2 (en) 2008-09-02 2012-03-22 Addex Pharma S.A. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
RU2517181C2 (ru) 2008-10-16 2014-05-27 Орто-Макнейл-Янссен Фармасьютикалз, Инк. Производные индола и бензоморфолина в качестве модулятора метаботропных глутаматных рецепторов
CA2744138C (en) 2008-11-28 2015-08-11 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906472D0 (en) * 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
AU2010246609B2 (en) 2009-05-12 2013-09-05 Addex Pharma S.A. 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
EA020671B1 (ru) 2009-05-12 2014-12-30 Янссен Фармасьютикалз, Инк. ПРОИЗВОДНЫЕ 1,2,4-ТРИАЗОЛО[4,3-a]ПИРИДИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ mGluR2
PL2475428T3 (pl) 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
FR2950344B1 (fr) * 2009-09-18 2011-11-25 Sanofi Aventis Derives de 5-phenyl-pyrazolopyridine, leur preparation et leur aplication en therapeutique.
FR2950345B1 (fr) * 2009-09-18 2011-09-23 Sanofi Aventis Derives acetyleniques de 5-phenyl-pyrazolopyridine, leur preparation et leur application en therapeutique
CA2778265A1 (en) * 2009-11-02 2011-05-05 Abbott Laboratories Imidazopyridines as a novel scaffold for multi-targeted kinase inhibition
FR2953520B1 (fr) * 2009-12-04 2011-11-25 Sanofi Aventis Derives de diphenyl-pyrazolopyridines, leur preparation et leur application en therapeutique
EP2338888A1 (en) * 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
EP2360158A1 (en) * 2010-02-18 2011-08-24 Almirall, S.A. Pyrazole derivatives as jak inhibitors
UY33213A (es) * 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
EP2565185A1 (en) * 2010-04-28 2013-03-06 Daiichi Sankyo Company, Limited [5,6]heterocyclic compound
EP2632903A4 (en) * 2010-10-28 2014-11-26 Viamet Pharmaceuticals Inc METALLOENZYMHEMMERVERBINDUNGEN
US9271967B2 (en) 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
WO2012062751A1 (en) 2010-11-08 2012-05-18 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
CN103298809B (zh) 2010-11-08 2016-08-31 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
PL2651939T3 (pl) 2010-12-13 2015-10-30 Array Biopharma Inc Podstawione związki N-(1H-indazol-4-ylo)imidazo[1,2-a]pirydyno-3-karboksyamidu jako inhibitory receptorowych kinaz tyrozynowych typu III
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
EP2554544A1 (en) 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
UA111382C2 (uk) 2011-10-10 2016-04-25 Оріон Корпорейшн Інгібітори протеїнкінази
EP3176170B1 (en) 2012-06-13 2018-11-14 Incyte Holdings Corporation Substituted tricyclic compounds as fgfr inhibitors
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
WO2014051698A1 (en) 2012-09-28 2014-04-03 Vanderbilt University Fused heterocyclic compounds as selective bmp inhibitors
CN102898426B (zh) * 2012-11-15 2015-04-22 江苏先声药业有限公司 抑制igf-1r酪氨酸激酶活性的吡啶并吡唑类衍生物
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
AR094812A1 (es) 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
TWI628176B (zh) * 2013-04-04 2018-07-01 奧利安公司 蛋白質激酶抑制劑
SG10201708520YA (en) 2013-04-19 2017-12-28 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
WO2014176259A1 (en) 2013-04-22 2014-10-30 Icahn School Of Medicine At Mount Sinai Mutations in pdgfrb and notch3 as causes of autosomal dominant infantile myofibromatosis
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
MX368443B (es) 2013-12-06 2019-10-02 Genentech Inc Inhibidores de serina/treonina cinasa.
HUE045610T2 (hu) 2014-01-21 2020-01-28 Janssen Pharmaceutica Nv 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait vagy ortosztérikus agonistáit tartalmazó kombinációk és alkalmazásuk
WO2015110435A1 (en) 2014-01-21 2015-07-30 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
WO2016011019A1 (en) * 2014-07-15 2016-01-21 The Brigham And Women's Hospital, Inc. Compositions and methods for inhibiting bmp
ES2914072T3 (es) 2014-08-18 2022-06-07 Eisai R&D Man Co Ltd Sal de derivado de piridina monocíclico y su cristal
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MX373169B (es) 2015-02-20 2020-04-24 Incyte Holdings Corp Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr).
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
ES2887148T3 (es) 2015-03-25 2021-12-21 Nat Cancer Ct Agente terapéutico contra el cáncer de vías biliares
CN115177619A (zh) 2015-12-17 2022-10-14 卫材R&D管理有限公司 用于乳腺癌的治疗剂
CN110430880A (zh) * 2017-01-18 2019-11-08 范德比尔特大学 作为选择性bmp抑制剂的稠合杂环化合物
JP7205018B2 (ja) * 2017-03-23 2023-01-17 アウリジーン ディスカバリー テクノロジーズ リミテッド スルホンアミド構造のキナーゼ阻害剤の製造方法
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
EP3703675A4 (en) 2017-10-30 2021-06-16 Neuropore Therapies, Inc. SUBSTITUTED PHENYLSULFONYLPHÉNYLTRIAZOLETHIONES AND ASSOCIATED USES
TWI816742B (zh) 2018-01-29 2023-10-01 美商維泰克斯製藥公司 Gcn2抑制劑及其用途
MX2020007797A (es) * 2018-01-29 2020-09-18 Merck Patent Gmbh Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
US10745400B2 (en) 2018-03-14 2020-08-18 Vanderbuilt University Inhibition of BMP signaling, compounds, compositions and uses thereof
EP3777860A4 (en) 2018-03-28 2021-12-15 Eisai R&D Management Co., Ltd. THERAPEUTIC FOR HEPATOCELLULAR CARCINOMA
CR20240498A (es) 2018-05-04 2025-01-08 Incyte Corp FORMAS SÓLIDAS DE UN INHIBIDOR DE FGFR Y PROCESOS PARA PREPARARLAS (Divisional EXP. 2020-0590)
BR112020022373A2 (pt) 2018-05-04 2021-02-02 Incyte Corporation sais de um inibidor de fgfr
CN113490667B (zh) * 2018-12-29 2023-10-27 盛世泰科生物医药技术(苏州)股份有限公司 作为fgfr和vegfr双重抑制剂的咪唑并吡啶衍生物
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
CN113993867B (zh) * 2019-06-14 2023-10-24 盛世泰科生物医药技术(苏州)股份有限公司 作为fgfr和vegfr双重抑制剂的并环类化合物
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12378241B2 (en) 2019-07-26 2025-08-05 Cgenetech (Suzhou,China) Co., Ltd. Pyridine derivative as FGFR and VEGFR dual inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JOP20220083A1 (ar) 2019-10-14 2023-01-30 Incyte Corp حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
PE20221504A1 (es) 2019-12-04 2022-09-30 Incyte Corp Derivados de un inhibidor de fgfr
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2022161408A1 (zh) * 2021-01-26 2022-08-04 南京明德新药研发有限公司 甲基吡唑取代的吡啶并咪唑类化合物的晶型及其制备方法
EP4323405A1 (en) 2021-04-12 2024-02-21 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
EP4352059A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
JP2024522188A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式ヘテロ環

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4503050A (en) 1983-06-02 1985-03-05 Riker Laboratories, Inc. Substituted imidazo[1,2-c]pyrimidines
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
EP0308020A3 (en) 1987-09-18 1990-12-05 Merck & Co. Inc. 5-(aryl and heteroaryl)-6-(aryl and heteroaryl)-1,2-dihydro-2-oxo 3-pyridinecarboxylic acids and derivatives thereof
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5554630A (en) 1993-03-24 1996-09-10 Neurosearch A/S Benzimidazole compounds
EP0767790B1 (en) 1994-06-20 2001-12-12 Takeda Chemical Industries, Ltd. Condensed imidazole compounds, their production and use
JPH11505524A (ja) 1995-05-01 1999-05-21 藤沢薬品工業株式会社 イミダゾ１，２−ａピリジンおよびイミダゾ１，２−ａピリデジン誘導体、および骨吸収阻害剤としてのその用途
WO1998004689A1 (en) 1995-07-31 1998-02-05 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
AU6966696A (en) 1995-10-05 1997-04-28 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
DE69738197T2 (de) 1996-07-24 2008-07-17 Bristol-Myers Squibb Pharma Co. Azolotriazine und pyrimidine
JP2002501532A (ja) 1997-05-30 2002-01-15 メルク エンド カンパニー インコーポレーテッド 新規血管形成阻害薬
US5990146A (en) 1997-08-20 1999-11-23 Warner-Lambert Company Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation
WO2000012089A1 (en) 1998-08-31 2000-03-09 Merck & Co., Inc. Novel angiogenesis inhibitors
US6465484B1 (en) 1997-09-26 2002-10-15 Merck & Co., Inc. Angiogenesis inhibitors
SI1049699T1 (en) 1998-01-28 2004-10-31 Bristol-Myers Squibb Pharma Company Pyrazolotriazines as crf antagonists
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
DE60006541D1 (de) 1999-06-30 2003-12-18 Merck & Co Inc Src-kinase hemmende verbindungen
CA2376951A1 (en) 1999-06-30 2001-01-04 Peter J. Sinclair Src kinase inhibitor compounds
US6329380B1 (en) 1999-06-30 2001-12-11 Merck & Co., Inc. SRC kinase inhibitor compounds
JP2001057292A (ja) 1999-08-20 2001-02-27 Toray Ind Inc 発光素子
GB9919778D0 (en) * 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
GB9921150D0 (en) 1999-09-07 1999-11-10 Merck Sharp & Dohme Therapeutic agents
WO2001021634A1 (en) 1999-09-21 2001-03-29 Lion Bioscience Ag Benzimidazole derivatives and combinatorial libraries thereof
GB9927687D0 (en) 1999-11-23 2000-01-19 Merck Sharp & Dohme Therapeutic agents
US7105550B2 (en) * 2000-03-01 2006-09-12 Christopher Love 2,4-disubstituted thiazolyl derivatives
KR20020081424A (ko) 2000-03-09 2002-10-26 아벤티스 파마 도이칠란트 게엠베하 Ｐｐａｒ 매개인자의 치료학적 용도
US20020041880A1 (en) 2000-07-05 2002-04-11 Defeo-Jones Deborah Method of treating cancer
WO2002012238A2 (en) 2000-08-04 2002-02-14 Warner-Lambert Company 2-(4-PYRIDYL)AMINO-6-DIALKOXYPHENYL-PYRIDO[2,3-d]PYRIMIDIN-7-ONES
AU2001295992A1 (en) 2000-10-24 2002-05-06 Sankyo Company Limited Imidazopyridine derivatives
GB0027561D0 (en) 2000-11-10 2000-12-27 Merck Sharp & Dohme Therapeutic agents
EP1341768A1 (en) 2000-12-07 2003-09-10 AstraZeneca AB Therapeutic benzimidazole compounds
US20020107262A1 (en) 2000-12-08 2002-08-08 3M Innovative Properties Company Substituted imidazopyridines
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
CA2435177A1 (en) 2001-02-20 2002-08-29 Astrazeneca Ab 2-arylamino-pyrimidines for the treatment of gsk3-related disorders
SE0100568D0 (sv) 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
SE0100567D0 (sv) 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
TWI248936B (en) 2001-03-21 2006-02-11 Merck Sharp & Dohme Imidazo-pyrimidine derivatives as ligands for GABA receptors
DE10117183A1 (de) 2001-04-05 2002-10-10 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]-pyridinverbindungen als Arzneimittel
JP4310109B2 (ja) 2001-04-26 2009-08-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾリル基を置換基として有する含窒素縮合環化合物およびその医薬組成物
AU2002317377A1 (en) 2001-07-20 2003-03-03 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
GB0128499D0 (en) 2001-11-28 2002-01-23 Merck Sharp & Dohme Therapeutic agents
US6900208B2 (en) 2002-03-28 2005-05-31 Bristol Myers Squibb Company Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
WO2003091256A1 (en) 2002-04-23 2003-11-06 Shionogi & Co., Ltd. PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE AND NAD(P)H OXIDASE INHIBITOR CONTAINING THE SAME
JP2004002826A (ja) 2002-04-24 2004-01-08 Sankyo Co Ltd 高分子イミダゾピリジン誘導体
AU2003241326B2 (en) 2002-05-02 2008-05-01 Merck & Co., Inc. Tyrosine kinase inhibitors
AU2003229370B2 (en) * 2002-05-23 2009-02-26 Ym Biosciences Australia Pty Ltd Kinase inhibitors
AUPS251402A0 (en) * 2002-05-23 2002-06-13 Cytopia Pty Ltd Kinase inhibitors
GB0212048D0 (en) 2002-05-24 2002-07-03 Merck Sharp & Dohme Therapeutic agents
GB0212049D0 (en) 2002-05-24 2002-07-03 Merck Sharp & Dohme Therapeutic agents
MXPA04012245A (es) 2002-06-04 2005-09-30 Neogenesis Pharmaceuticals Inc Compuestos de pirazolo[1,5a]pirimidina como agentes antivirales.
US7196090B2 (en) 2002-07-25 2007-03-27 Warner-Lambert Company Kinase inhibitors
EP1539756B1 (en) 2002-09-19 2007-11-14 Schering Corporation Imidazopyridines as cyclin dependent kinase inhibitors
GB0223349D0 (en) 2002-10-08 2002-11-13 Merck Sharp & Dohme Therapeutic agents
WO2004035579A1 (ja) 2002-10-15 2004-04-29 Takeda Pharmaceutical Company Limited イミダゾピリジン誘導体、その製造法および用途
AU2003299651A1 (en) 2002-12-11 2004-06-30 Merck And Co., Inc. Tyrosine kinase inhibitors
US7262199B2 (en) 2002-12-11 2007-08-28 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2004075021A2 (en) 2003-02-14 2004-09-02 Vertex Pharmaceuticals, Inc. Molecular modeling methods
FR2851248B1 (fr) * 2003-02-18 2005-04-08 Aventis Pharma Sa Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
US7476670B2 (en) 2003-02-18 2009-01-13 Aventis Pharma S.A. Purine derivatives, method for preparing, pharmaceutical compositions and novel use
US7157460B2 (en) 2003-02-20 2007-01-02 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
WO2004087153A2 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
US7885960B2 (en) 2003-07-22 2011-02-08 Microsoft Corporation Community mining based on core objects and affiliated objects
CN1839132A (zh) 2003-08-21 2006-09-27 Osi制药公司 作为c－kit抑制剂的n3－取代的咪唑并吡啶衍生物
UA82395C2 (en) 2003-08-21 2008-04-10 Оси Фармасьютикалз, Инк. N-substituted benzimidazolyl c-kit inhibitors
US7442709B2 (en) 2003-08-21 2008-10-28 Osi Pharmaceuticals, Inc. N3-substituted imidazopyridine c-Kit inhibitors
WO2005054230A1 (en) * 2003-12-03 2005-06-16 Cytopia Research Pty Ltd Azole-based kinase inhibitors
JP2007519720A (ja) 2004-01-28 2007-07-19 スミスクライン ビーチャム コーポレーション チアゾール化合物
TW200530236A (en) 2004-02-23 2005-09-16 Chugai Pharmaceutical Co Ltd Heteroaryl phenylurea
WO2005108399A1 (ja) 2004-05-10 2005-11-17 Banyu Pharmaceutical Co., Ltd. イミダゾピリジン化合物
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
EP1790650B1 (en) 2004-08-31 2014-03-26 Msd Kk NEW SUBSTITUTED IMIDAZOLE DERIVATIVES
EP1809294A4 (en) 2004-09-21 2008-08-06 Synta Pharmaceuticals Corp COMPOUNDS AGAINST INFLAMMATION AND IMMUNE-RELEVANT USES
WO2006038001A1 (en) 2004-10-06 2006-04-13 Celltech R & D Limited Aminopyrimidine derivatives as jnk inhibitors
US7419995B2 (en) 2004-12-01 2008-09-02 Osi Pharmaceuticals, Inc. N-substituted benzimidazoyl c-Kit inhibitors and combinatorial benzimidazole library
US20080167314A1 (en) 2004-12-28 2008-07-10 Osamu Uchikawa Condensed Imidazole Compound And Use Thereof
US20100160324A1 (en) 2004-12-30 2010-06-24 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
DOP2006000051A (es) * 2005-02-24 2006-08-31 Lilly Co Eli Inhibidores de vegf-r2 y métodos
US7998974B2 (en) 2005-03-03 2011-08-16 Sirtris Pharmaceuticals, Inc. Fused heterocyclic compounds and their use as sirtuin modulators
MX2007012393A (es) 2005-04-05 2008-02-22 Pharmacopeia Inc Derivados de purina e imidazopiridina para la inmunosupresion.
FR2884821B1 (fr) 2005-04-26 2007-07-06 Aventis Pharma Sa Pyrrolopyridines substitues, compositions les contenant, procede de fabrication et utilisation
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
CA2623374A1 (en) 2005-09-30 2007-04-05 Astrazeneca Ab Imidazo [1,2-a] pyridine having anti-cell-proliferation activity
AU2007227210A1 (en) 2006-03-20 2007-09-27 Synta Pharmaceuticals Corp. Benzoimidazolyl-parazine compounds for inflammation and immune-related uses
AU2007230911A1 (en) 2006-03-23 2007-10-04 Synta Pharmaceuticals Corp. Benzimidazolyl-pyridine compounds for inflammation and immune-related uses
ITVA20060041A1 (it) 2006-07-05 2008-01-06 Dialectica Srl Uso di composti derivati amminotiazolici, di loro composizioni farmaceutiche, nel trattamento di malattie caratterizzate dalla anormale repressione della trascrizione genica, particolarmente il morbo di huntington
TW200811134A (en) 2006-07-12 2008-03-01 Irm Llc Compounds and compositions as protein kinase inhibitors
EP1882475A1 (en) 2006-07-26 2008-01-30 Novartis AG Method of treating disorders mediated by the fibroblast growth factor receptor
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
AR064491A1 (es) 2006-12-22 2009-04-08 Astex Therapeutics Ltd Derivados de imidazo[1, 2-a]pirimidina, un proceso para su preparacion, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por las quinasas fgfr.
WO2008078100A2 (en) 2006-12-22 2008-07-03 Astex Therapeutics Limited Tricyclic amine derivatives as protein tyrosine kinase inhibitors
US8131527B1 (en) 2006-12-22 2012-03-06 Astex Therapeutics Ltd. FGFR pharmacophore compounds
US7977336B2 (en) 2006-12-28 2011-07-12 Banyu Pharmaceutical Co. Ltd Aminopyrimidine derivatives as PLK1 inhibitors
AU2008237507B2 (en) 2007-04-03 2014-03-20 Array Biopharma Inc. Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
ES2602615T3 (es) 2007-06-12 2017-02-21 Achaogen, Inc. Agentes antibacterianos
JP2010531875A (ja) 2007-06-26 2010-09-30 ギリード・サイエンシズ・インコーポレーテッド イミダゾピリジニルチアゾリルヒストンデアセチラーゼ阻害剤
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds

Also Published As

Publication number Publication date
AU2007337895B2 (en) 2014-01-30
NO20092658L (no) 2009-09-17
JP5442449B2 (ja) 2014-03-12
US8513276B2 (en) 2013-08-20
EP2121687A2 (en) 2009-11-25
PL2121687T3 (pl) 2016-03-31
JP2010513448A (ja) 2010-04-30
AU2007337895A1 (en) 2008-07-03
CN101679409B (zh) 2014-11-26
CA2672213A1 (en) 2008-07-03
CN101679409A (zh) 2010-03-24
WO2008078100A2 (en) 2008-07-03
AU2007337895C1 (en) 2014-07-31
NO342865B1 (no) 2018-08-20
HRP20151398T1 (hr) 2016-02-12
EP2121687B1 (en) 2015-10-14
WO2008078100A3 (en) 2008-11-13
CY1117319T1 (el) 2017-04-26
US20100093718A1 (en) 2010-04-15
CA2672213C (en) 2016-02-16

Similar Documents

Publication Publication Date Title
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
MX2009006706A (es) Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
BRPI0915084B8 (pt) composto, e, composição farmacêutica
PH12011502704A1 (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
IL192763A (en) History of pyrimidine, preparations containing them and used in the preparation of cancer drugs
MY149957A (en) Heterocyclic inhibitors of mek and methods of use thereof
PH12014500053A1 (en) Proteasome inhibitors
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
IN2012MN02591A (enExample)
MX361467B (es) Compuestos de isoindolina para uso en el tratamiento de cancer.
CL2007000806A1 (es) Compuestos derivados de heteropentaciclos sustituidos; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento del cancer.
TW200714604A (en) Substituted heterocycles and the uses thereof
ZA200805163B (en) Isoquinoline aminopyrazole derivatives, their manufacture and use as pharmaceutical agents for the treatment of cancer
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
CL2007000161A1 (es) Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
MX2009007337A (es) Indazoles sustituidos con 5-piridinona.
UA96785C2 (uk) Заміщені похідні оксиндолу та їх застосування як лігандів рецептора вазопресину
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
UA104988C2 (uk) Похідні піроніндолу та спосіб їх отримання
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
WO2010121164A3 (en) 1,4-benzodiazepinone compounds and their use in treating cancer
IL192415A0 (en) Pharmaceutical composition for the treatment of nail diseases
TW200724537A (en) Pyrimidine derivatives for treatment of hyperproliferative disorders
MY164998A (en) Isoquinolinone derivatives as nk3 antagonists
FI20095600L (fi) Koostumus ihosairauksien hoitoa varten

Legal Events

Date Code Title Description
FG Grant or registration